News
Media
Medical World NewsPodcastsVideosInsightsPeer ExchangeMedia DayNews NetworkRoundtables
Conference
Conference CoverageConference Listing
Publication
More
CME/CE
Partners
Resources
Interactive ToolsSpecial ProjectsSponsored
Contribute
Case StudiesWriters and Mentors

Subscribe

  • News
  • Media
  • Conference
  • Publication
  • CME/CE
  • Partners
  • Resources
  • Contribute
  • Subscribe
  • Antimicrobial Stewardship
  • Blood-Borne Diseases
    • Ebola
    • HCV / Hepatitis
  • Coronavirus / COVID
  • Food Borne Infection / Food Safety
    • E. Coli
    • Food Safety
    • Listeria
    • Salmonella
  • Fungal Infections
    • Candida auris
  • Gastrointestinal Infections
    • C. Difficile
    • H. Pylori
    • Norovirus
  • Healthcare Associated Infections (HAI)
  • Prevention
    • Antibiotics
    • Immunizations
    • Vaccines
  • Respiratory Infections
    • Community-Acquired Pneumonia
    • Measles
    • Influenza
  • Sexually Transmitted Diseases
    • HIV / AIDS
    • HPV
    • HSV
    • PrEP
  • Skin & Soft Tissue Diseases
    • MRSA
  • Zoonotic & Vector-Borne Diseases
    • Lyme Disease
    • ZIKA
Spotlight -
Antimicrobial Stewardship|
Bench to Bedside With SIDP|
C. difficile |
Clinical Corner|
Fungal Infections|
Hepatitis|
RSV: A New Era in Prevention
Advertisement

Umida Nasritdinova, PharmD Candidate

Advertisement

Articles by Umida Nasritdinova, PharmD Candidate

Vaginal Microbiome Transplantation Effective in Intractable Bacterial Vaginosis

ByUmida Nasritdinova, PharmD Candidate,Kirk E. Hevener, PharmD, PhD
December 9th 2019

A recent study reported the benefit of vaginal microbiome transplantation for the treatment of recurrent bacterial vaginosis.

Advertisement

Latest Updated Articles

  • Vaginal Microbiome Transplantation Effective in Intractable Bacterial Vaginosis
    Vaginal Microbiome Transplantation Effective in Intractable Bacterial Vaginosis

    Published: December 9th 2019 | Updated:



Advertisement
Advertisement

Trending on Contagion Live

1

New Data Highlight Adult Pneumococcal Serotypes with Greater Antibiotic Resistance and Disease Burden Covered by Merck’s Vaccine

2

Oral Carbapenem Tebipenem HBr Demonstrates Non-Inferiority to IV Therapy in Phase III PIVOT-PO Trial

3

Introducing Cefiderocol Earlier in Difficult-to-Treat-Infections

4

Developing a COVID-19 Vaccine Alternative

5

Lori Handy, MD, MSCE, Discusses New Era of Dynamic, Trust-Based Health Communication

  • About Us
  • Advertise
  • Editorial
  • Contact Us
  • Do Not Sell My Information
  • Privacy
  • Terms & Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us